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Elevated level of circulating matrix
metalloproteinase-9 in patients with lung cancer
E. HRABEC*, M. STREK*, D. NOWAK{ AND Z. HRABEC*
*Department of Biochemistry and {Department of Physiology, Medical University of Ło´dz´, Poland
The 72 kDa matrix metalloproteinase (MMP-2) and the 92 kDa matrix metalloproteinase (MMP-9), are type IV
collagenases that have been implicated as important factors in cancer invasion and metastasis formation. We have
used quantitative zymography and computer-assisted image analysis to measure the levels of MMP-9 and MMP-2
in 19 samples of serum of lung cancer patients and in 23 samples of normal serum. Mean levels of MMP-9 were
significantly elevated in cancer samples compared with normal sera (1?33+0?61 mU ml71 vs. 0?37+0?10mUml71,
P50?0001). MMP-2 levels did not differ significantly in these two groups. However, there was no significant
correlation between serum MMP-9 activity and the disease stage. We found that circulation levels of MMP-9 in
lung cancer patients is 3?6-fold higher than in healthy volunteers, however, we do not consider this elevation to be a
direct reflection of MMP-9 over-production by tumour cells.
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Matrix metalloproteinases (MMPs) are extracellular ma-
trix-degradative enzymes capable of degrading many
extracellular matrix proteins, including basement mem-
brane components such as type IV collagen (1). These
enzymes have been implicated in tumour invasion and
metastasis (2,3). Two MMPs have type IV collagenolytic
activity, namely 72 kDa type IV collagenase (MMP-2) and
92 kDa type IV collagenase (MMP-9). These enzymes are
expressed in many different human tumours including
carcinomas of the lung, colon, breast and prostate (4–8).
A search for specific proteins released into the circulation
by cancer cells is a feasible approach to detect early cancer
lesion. The possibility that MMP-2 and/or MMP-9 have
potential utility as serum or plasma markers is very
attractive and has been postulated by several authors (9–
12). Elevated levels of MMP-2 and/or MMP-9 in circula-
tion have been reported in patients with gastric (9,10),
colon (13), breast (13) and prostate (14) cancers. For lung
cancer patients, however, there is a discrepancy between the
data published by Zucker et al. (13) and Iizasa et al. (15).
Therefore, in the present study, in order to determineReceived 17 January 2000 and accepted in revised form 28 June
2000.
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0954-6111/01/010001+04 $35?00/0whether these enzymes might be useful tumour markers for
lung cancer, we measured the MMP-2 and MMP-9
activities in serum and plasma from normal subjects and
patients with lung cancer.
Materials and methods
STUDY POPULATIONS
The study subjects included 23 healthy volunteers and 19
patients with histologically or cytologically confirmed lung
cancer (Table 1). Healthy subjects with no history of
respiratory disease had not suffered from any infectious
disease for at least 3 months prior to the study. Seven
patients had small-cell lung cancer (SCLC) (two had limited
disease, five had extensive disease) and the rest revealed
non-small-cell lung cancer (NSCLC) (10 had squamous cell
carcinoma, two had adenocarcinoma).
GELATIN ZYMOGRAPHY
Gelatin zymography was performed as described previously
(5). Briefly, an aliquot of serum or plasma (equivalent to
0?1–0?8 ml of undiluted serum or plasma) was subjected to
electrophoresis in a 10% polyacrylamide gel embedded with
1?5mgml71 gelatin. The enzymes were renatured by
incubation with 2?5% Triton X-100 and the enzyme
reaction was allowed to proceed at 378C for 21 h.# 2001 HARCOURT PUBLISHERS LTD
TABLE 1. Patients characteristics
Subjects Healthy subjects Lung cancer subjects
Whole group SCLC NSCLC
Number 23 19 7 12
Sex (F/M) 11/12 6/13 3/4 3/9
Age 56+12 61+10 53+10 66+8
WBC6103ml71 6?7+1?9 8?5+5?0 7?7+1?5 9?0+6?4
Neutrophils6103ml71 4?7+1?2 5?9+3?2 5?2+1?0 6?3+4?0
Hb g dl71 14?6+1?7 13?5+4?1 13?8+1?2 13?4+1?6
Current smokers 20 17 7 10
Ex-smokers 1 1 0 1
Never smoked 2 1 0 1
SCLC: small-cell lung cancer; NSCLC: non-small-cell lung cancer; WBC: white blood cell count. The NSCLC subgroup
included 10 subjects with squamous cell carcinoma and two with adenocarcinoma. Two patients had stage II disease, five
stage III A and five stage III B disease. In the SCLC subgroup two patients had limited disease and five extensive disease.
The present cigarette consumption was 17?7+7 cigaretes a day and 21+9 pack-years for lung cancer subjects, and 14+6
cigarettes a day and 19+7 pack-years for healthy controls, respectively.
FIG. 1. Example of a zymogram for healthy volunteers
(a–d), lung cancer patients’ sera (e–h) and type IV
coallgenases’ standards (i) are shown. Lanes a–h contain
an equivalent of 0?8ml undiluted serum. Lane i contains
0?4mU of MMP-2 and 0?2mU of MMP-9.
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Stained gels were captured using a video camera (Image
Master VDS, Pharmacia Biotech) equipped with a Compaq
personal computer and images were analysed with Image
Master VDS software. In order to establish the linear range
of relationships between the activities of MMPs and
integrated optical density (IOD) of the lysis bands,
zymograms containing increasing activities of commercial
MMP-2 and MMP-9 (Boehringer Mannheim) were ana-
lysed. The detection limits were 0?08mU per lane and
0?1mU per lane for MMP-2 and MMP-9, respectively. The
mean intra-assay variation (n=5) was 6?8% for MMP-2
and 7?5% for MMP-9. The mean inter-assay variation was
15?4% for MMP-2 and 17?3% for MMP-9. For quantita-
tive analysis, internal standards (commercial MMP-2 and/
or MMP-9) were electrophoresed on two lanes in each gel.
The activities of MMP-2 and MMP-9 were expressed in
mU ml71 serum and mUml71 serum, respectively. Accord-
ing to the manufacturer’s product specification sheet 1 unit
of MMP-2 is the activity that hydrolyses 1mg of type IV
collagen within 1 h at 378C. One unit of MMP-9 is the
activity that hydrolyses 1 mmol of DNP-peptide within 1
min at 378C.
Statistical comparisons were performed with Stat-
graphics Plus version 2?1 software (Statistical Graphics
Corporation, U.S.A.). P-values were calculated using
Mann—Whitney W-test. A P-value of less than 0?05 was
considered to be significant.
Results and discussion
Serum type IV collagenases were investigated by means of
gelatin-embedded polyacrylamide gel electrophoresis fol-lowed by incubation. A typical zymographic pattern is
presented in Fig. 1. On each electrophoretic lane an
equivalent of 0?8ml undiluted serum of healthy volunteers
and lung cancer patients were electrophoresed. Figure 1 is a
good illustraion of differences in MMP-9 levels between
control and cancer serum, however, for the quantitative
purpose, the volume of lung cancer patients serum
electrophoresed samples was at least threefold smaller than
the control serum. Since the activities of MMP-2 and
MMP-9 against gelatin are imbalanced, for quantitative
purposes, we analysed these enzymes in separate electro-
phoretic runs.
As shown in Fig. 2 the MMP-9 activity was 3?6-fold
higher (P50?00001) in serum of lung cancer patients than
in healthy subjects (1?33+0?61 mUml71, n=19 vs.
0?37+0?10 mU ml71, n=23), whereas MMP-2 activity did
FIG. 2. Serum MMP-9 and MMP-2 levels in healthy
volunteers (&) and patients with lung cancer (&) are
illustrated. The cut-off value of MMP-9 (0?57mUml71)
was determined by the mean levelþ2 SD of healthy
controls. NS: not significant.
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were also tested in control volunteers’ plasma samples
(n=6) and in lung cancer patients’ plasma samples (n=6).
In both groups tested, MMP-2 activities were comparable
in serum as well as in plasma samples in the range of
analytical precision. MMP-9 activities tested in plasma
were about twofold lower than tested in serum, however,
the ratio of MMP-9 activities in cancer to normal plasma
were on the same level as for serum samples (3?42 and 3?59
respectively).
If the cut-off value for the normal serum activity of
MMP-9 was determined by the mean levelþ2 SD of the
healthy controls (0?57mUml71), only one patient with lung
cancer was shown to have serum MMP-9 level below this
border. However, like Iizasa et al. (15), we did not observe
any significant correlation between serum MMP-9 activity
and the disease stage.
Our results are consistent with the findings obtained by
Iizasa et al. (15) despite using a different methodology.
However, Zucker et al. (13) did not observe the elevation of
MMP-9 activity in plasma of patients with lung cancer.
This discrepancy is even more dicult to explain because,
using the same monoclonal antibody to human MMP-9
and a sandwich ELISA detection system, they were able to
demonstrate an elevated plasma MMP-9 concentration in
patients with breast and gastrointestinal cancer.
An interesting aspect raised by some reports is the
cellular source of MMPs affecting the elevation of plasma
levels of these enzymes in cancer patients. It has been
suggested that the rise in circulating MMP-9 and/or MMP-
2 levels in cancer patients reflects enhanced secretion of
these enzymes by invasive cells (11–13). However, accord-
ing to results of our previous study (5), in lung cancer the
greatest difference between normal and neoplastic tissues is
the over-expression of both type IV collagenases with theactivation of, first of all, MMP-2 appearing to be a feature
of a malignant phenotype. Activation of MMPs is
independent of their synthesis, however; if elevated serum
level of MMP-9 was connected with augmented enzyme
secretion by neoplastic cells accompanied by its activation,
then active MMPs should be also visible in circulation. A
zymographic test is capable of discriminating the active
enzymes from their latent forms. However, in no case were
the active MMPs visible in serum or plasma samples of lung
cancer patients. Thus, we do not presume that the elevation
of lung cancer patients’ serum MMP-9 levels are a direct
reflection of increased secretion of this enzyme by
neoplastic cells. An alternative explanation of this phenom-
enon is that the elevation of MMP-9 levels in circulation of
lung cancer patients is affected by augmentation of
synthesis and/or secretion of this enzyme by some blood
cells. Human neutrophils, eosinophils, lymphocytes and
monocytes have the capacity to synthesize MMP-9, but
apart from T lymphocytes none of these cells is able to
express MMP-2. So, the fact that elevation of serum type
IV collagenases concerned MMP-9 but not MMP-2 is the
case for this hypothesis. MMP-9 is an inducible enzyme and
recent reports suggest that its activity is regulated by
numerous cytokines, chemotactic peptides and growth
factors (16–18).
Our cancer subjects had no clinical signs of co-existing
airway infection. However, it cannot be excluded that
MMP-9 can exhibit some properties characteristic of an
acute phase protein. Results of study show that in lung
cancer patients the serum MMP-9 levels were not sig-
nificantly correlated with leukocyte counts or neutrophil
counts of whole blood. Thus, the elevation of MMP-9
observed in lung cancer patients seems not to be a direct
consequence of elevated number of leukocytes. In this
connection, it cannot be ruled out that the elevation of
serum MMP-9 levels in lung cancer patients is affected by
the augmentation of synthesis or secretion of this enzyme
by some inflammatory cells via cytokine(s) or growth
factor(s) secreted by cancer cells. However, this hypothesis
must be followed by further study. Elevated MMP-9 levels
have been observed in the bronchoalveolar lavage fluid
(19,20) and nasal washings (21) of asthmatic patients after
allergen provocation. On the other hand, there was no
difference in circulating levels of MMP-9 in subjects with or
without an acute systemic inflammatory process like adult
respiratory distress syndrome and/or multiple organ failure
(22).
In summary, we observed that the levels of serum or
plasma MMP-9 in lung cancer patients were significantly
higher than those of healthy subjects, but it cannot be
accepted with certainty that this phenomenon is directly
related to over-expression of this enzyme by cancer cells.
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